Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f - 2The Strait of Hormuz Isn’t Just an Oil Problem, It’s Now a Food Problem
- 3Manual for Mountain Objections on the planet
- 4Why the weirdest sea level changes on Earth are happening off the coast of Japan
- 5AfD faction in western Germany ousts councilman for firebrand speech
- New images reveal interstellar comet 3I/ATLAS approaching Earth
- Ifo: Job cuts in Germany slowing but not enough for a turnaround
- Parents search for children missing since a volcanic eruption in Colombia 40 years ago
- Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- Best Disney Palace: Which One Catches Your Creative mind?
- What is colostrum? And should you be taking it?
- Palestinians protest against Israel's new death penalty law
- Pain at the pump for Hampton Roads residents
- The most effective method to Safeguard Your Teeth from Acidic Food varieties and Beverages
